Business Wire07.19.18
Corindus Vascular Robotics Inc., a developer of precision vascular robotics, has received Pharmaceutical and Medical Device Agency (PMDA) approval for commercialization of its CorPath GRX System in Japan. Japan is one of the largest markets in the world for percutaneous coronary interventions (PCI), with approximately 250,0001 PCI procedures performed annually.
Corindus is actively pursuing reimbursement for robotic PCI through the Japanese insurance system and plans a post-market study of CorPath GRX. In early 2017, Corindus announced a strategic relationship with Japan Medicalnext Co. Ltd., a wholly-owned entity of MC Healthcare Inc. (subsidiary of Mitsubishi Corporation), to become the exclusive distributor of Corindus products in Japan, bringing robotic precision and control to the large and growing PCI segment of the Japanese healthcare market.
"There is strong demand for robotic-assisted intervention from Key Opinion Leaders and the broad clinical community in Japan. PMDA approval of CorPath GRX in Japan represents a significant step in our ongoing effort to bring cutting-edge vascular robotics to global markets," stated Mark Toland, president and CEO of Corindus Vascular Robotics. "We believe robotics has the potential to enhance patient care in Japan by offering the benefits of robotic precision and advanced tools for physicians to perform these life-saving procedures."
"I look forward to offering CorPath GRX to my patients during PCI, especially in complex procedures where precision and procedural control are extremely valuable," said Takafumi Ueno, M.D., Ph.D., director of interventional cardiology for the Center of Cardiovascular Disease at Kurume University Hospital. "We are pleased to be one of the first Asia-Pacific countries to adopt this new technology."
Corindus Vascular Robotics Inc. develops robotic-assisted vascular interventions. The company's CorPath System is the first U.S. Food and Drug Administration-cleared medical device to bring robotic precision to percutaneous coronary and percutaneous vascular procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. CorPath GRX is the second generation robotic-assisted PCI technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures.
Corindus is actively pursuing reimbursement for robotic PCI through the Japanese insurance system and plans a post-market study of CorPath GRX. In early 2017, Corindus announced a strategic relationship with Japan Medicalnext Co. Ltd., a wholly-owned entity of MC Healthcare Inc. (subsidiary of Mitsubishi Corporation), to become the exclusive distributor of Corindus products in Japan, bringing robotic precision and control to the large and growing PCI segment of the Japanese healthcare market.
"There is strong demand for robotic-assisted intervention from Key Opinion Leaders and the broad clinical community in Japan. PMDA approval of CorPath GRX in Japan represents a significant step in our ongoing effort to bring cutting-edge vascular robotics to global markets," stated Mark Toland, president and CEO of Corindus Vascular Robotics. "We believe robotics has the potential to enhance patient care in Japan by offering the benefits of robotic precision and advanced tools for physicians to perform these life-saving procedures."
"I look forward to offering CorPath GRX to my patients during PCI, especially in complex procedures where precision and procedural control are extremely valuable," said Takafumi Ueno, M.D., Ph.D., director of interventional cardiology for the Center of Cardiovascular Disease at Kurume University Hospital. "We are pleased to be one of the first Asia-Pacific countries to adopt this new technology."
Corindus Vascular Robotics Inc. develops robotic-assisted vascular interventions. The company's CorPath System is the first U.S. Food and Drug Administration-cleared medical device to bring robotic precision to percutaneous coronary and percutaneous vascular procedures. During the procedure, the interventional cardiologist sits at a radiation-shielded workstation to advance guide catheters, stents, and guidewires with millimeter-by-millimeter precision. The workstation allows the physician greater control and the freedom from wearing heavy lead protective equipment that causes musculoskeletal injuries. CorPath GRX is the second generation robotic-assisted PCI technology offering enhancements to the platform by adding important key upgrades that increase precision, improve workflow, and extend the capabilities and range of procedures that can be performed robotically. With the CorPath System, Corindus Vascular Robotics brings robotic precision to interventional procedures to help optimize clinical outcomes and minimize the costs associated with complications of improper stent placement during manual procedures.